Italy's prestigious Veneto Institute of Oncology acquires MILabs' latest VECTor5CT system

The Istituto Oncologico Veneto (IOV) has acquired MILabs’ latest generation VECTor⁵CT as a key imaging tool to support its translational oncology mission, entrusted by the Italian Ministry of Health and the Organization of the European Cancer Institutes. Due to its high-resolution imaging capabilities, MILabs’ preclinical Versatile Emission Computed Tomography system (“VECTor”) is very well suited to enable a quick translation of molecular research from the bench to the clinic at the IOV.

According to Prof. Antonio Rosato, Deputy Scientific Director and in charge of the preclinical imaging facility of the Institute:

We anticipate that the unique ability of the MILabs system to image tumors with high-definition PET, SPECT and CT modalities, further enhanced by high-resolution imaging of radiotherapeutic tracers such as ¹⁸⁸Re, will accelerate IOV’s research on the personalization of therapy in solid tumors.

Prof. Freek Beekman, CEO/CSO of MILabs B.V. adds:

We are confident that the unique diagnostic and theranostic imaging capabilities of the VECTor⁵CT will help IOV-IRCCS stay at the leading edge of bringing the latest scientific findings from the laboratory to the patient so it can keep offering the most innovative therapies.

By integrating multiple modalities on a single system, MILabs’ VECTor PET/SPECT/CT enables to expand diagnostic and treatment applications beyond the capabilities of any other preclinical imaging system including single-pass simultaneous PET and SPECT, dynamic molecular CT acquisitions as well as theranostic imaging with alpha- and beta- radiotherapy nuclides.